Bevacizumab Neoadjuvant Therapy for New High-grade Gliomas in the Brain

What this Trial Is About

This research focuses on patients with new-onset high-grade gliomas, a type of brain tumor known as glioblastoma (GBM) that grows diffusely and invades surrounding brain tissue. The tumor's aggressive nature and its tendency to recur shortly after surgery contribute to poor outcomes. GBM is characterized by abnormal blood vessel growth, and blocking this process is a key therapeutic approach. The study aims to evaluate the safety and effectiveness of bevacizumab, a drug that inhibits blood vessel growth in tumors, when given before surgery as an additional treatment. Participants receive bevacizumab administered intravenously at a dose of 5 mg/kg on days 1 and 15 before surgery. This treatment is intended to reduce tumor blood vessel formation and limit tumor growth. The study does not mention other treatment groups or comparators but focuses on assessing bevacizumab as a neoadjuvant therapy to potentially improve surgical outcomes. During the study, researchers will monitor participants for approximately two years to measure the objective response rate, which reflects how well the tumor responds to treatment. Assessments may include imaging and clinical evaluations to track tumor status and patient health. Safety and tolerability of bevacizumab will also be closely observed throughout the treatment and follow-up periods, ensuring comprehensive monitoring of outcomes and adverse events.

Bevacizumab Neoadjuvant Therapy for New High-grade Gliomas in the Brain